Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinoma
U. N. Wasko, J. Jiang, A. C. Garcia, Y. Wang, B. Lee, M. Orlen, K. Drizyte-Miller, M. Menard, J. Dilly, S. A. Sastra, C. F. Palermo, T. Dalton, M. C. Hasselluhn, A. R. Decker-Farrell, S. Chang, , R. H Vonderheide
This study evaluates the therapeutic potential of RMC-7977, a broad-spectrum RAS inhibitor, in pancreatic ductal adenocarcinoma models, showing strong anti-tumor effects with minimal impact on normal tissues.
bioRxiv · Dec 3, 2023 · PreprintCancer Biology